Xtant Medical Holdings has entered a partnership with B2i Digital to enhance investor awareness of its orthobiologics platform and market opportunities. This collaboration is set to provide centralized, investor-focused content, aiming to shed light on Xtant's comprehensive product line and its position in the regenerative medicine market.
The company's vertically integrated model encompasses a wide range of products, including bone-healing grafts and growth-factor biologics, supported by a strong R&D pipeline with next-generation biologics expected to launch by 2025. Xtant Medical reported a significant revenue increase to $117.5 million in fiscal year 2024, marking a 29% growth year-over-year.
David Shapiro, CEO of B2i Digital, highlighted the strategic timing of this partnership, noting Xtant's established distribution network and product pipeline as key factors for investor interest. Sean Browne, CEO of Xtant Medical, emphasized the partnership's role in communicating the company's growth narrative and value proposition to the investment community.
With access to a $2.5 billion U.S. orthobiologics market and a global spine market valued at $10.1 billion, Xtant Medical's collaboration with B2i Digital represents a strategic move to capitalize on its market position and growth trajectory.
